American Association for Clinical Chemistry; Australasian Association of Clinical Biochemists; Association for Clinical Biochemistry; The Royal College of Pathologists of Australasia. Tumour markers. 2012. www.labtestsonline.org.au/understanding/analytes/tumour-markers [cited 2012 Jul 6]

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-8.

Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-9.

Cancer Council Australia; Western Australian Clinical Oncology Group. Recommendations for screening and surveillance for specific cancers: guidelines for general practitioners. www.cancer.org.au/File/HealthProfessionals/CCA-Screening-Card-for-GPs.pdf [cited 2012 Jul 6]

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.

Sturgeon CM, Duffy MJ, Hofman BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical and gastric cancers. Clin Chem 2010; 56:e1-48.

Firkin F. Screening for multiple myeloma. Aust Prescr 2009; 32:92-4.

Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.

Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010;7:251-65.

Bean J, Brennan C, Shih JY, Riely G, Viale G, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7.

Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, Kennecke H, et al. Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. Curr Oncol 2010;17:39-45.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-20.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16.

Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.